Lenercept Biosimilar – Anti-TNF fusion protein – Research Grade

Description of Lenercept Biosimilar - Anti-TNF fusion protein - Research Grade

Lenercept Biosimilar: An Anti-TNF Fusion Protein for Therapeutic Targeting

Lenercept Biosimilar is a novel anti-tumor necrosis factor (TNF) fusion protein that has been developed as a potential therapeutic agent for various inflammatory and autoimmune diseases. This research grade protein is a biosimilar of the well-known anti-TNF drug, etanercept, and has shown promising results in pre-clinical studies. In this article, we will discuss the structure, activity, and potential applications of Lenercept Biosimilar in detail.

Structure of Lenercept Biosimilar

Lenercept Biosimilar is a fusion protein composed of two components – a human TNF receptor 2 (TNFR2) and the Fc fragment of human immunoglobulin G1 (IgG1). The TNFR2 component of Lenercept Biosimilar is responsible for binding to TNF, while the Fc fragment provides stability and prolongs the half-life of the protein in the body. The TNFR2 component consists of 277 amino acids and is attached to the Fc fragment through a flexible linker region. The overall molecular weight of Lenercept Biosimilar is approximately 150 kDa.

The structure of Lenercept Biosimilar is designed to mimic the structure and function of the natural TNF receptor. This allows for effective binding and neutralization of TNF, which is a key mediator of inflammation and immune response. The Fc fragment also plays a crucial role in the activity of Lenercept Biosimilar by enhancing its binding to TNF and promoting its clearance from the body.

Activity of Lenercept Biosimilar

The primary activity of Lenercept Biosimilar is the inhibition of TNF, a pro-inflammatory cytokine that is involved in various pathological conditions. TNF is produced by immune cells in response to infection, injury, or other triggers and plays a critical role in initiating and maintaining inflammation. In chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, and Crohn’s disease, TNF levels are significantly elevated, leading to tissue damage and disease progression.

Lenercept Biosimilar works by binding to TNF and preventing it from interacting with its receptors on immune cells. This blocks the downstream signaling pathways that lead to inflammation and tissue damage. By inhibiting TNF, Lenercept Biosimilar can effectively reduce the symptoms and progression of inflammatory and autoimmune diseases.

Applications of Lenercept Biosimilar

The potential applications of Lenercept Biosimilar are vast, given the central role of TNF in various diseases. It is currently being investigated as a potential treatment for rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. In pre-clinical studies, Lenercept Biosimilar has shown comparable efficacy and safety to etanercept, the reference anti-TNF drug.

In addition to its therapeutic applications, Lenercept Biosimilar can also be used as a research tool for studying the role of TNF in various diseases. Its specificity and potency make it a valuable tool for investigating the mechanism of action of TNF and its potential as a therapeutic target.

Conclusion

Lenercept Biosimilar is a promising anti-TNF fusion protein that has the potential to revolutionize the treatment of inflammatory and autoimmune diseases. Its unique structure, activity, and potential applications make it a valuable addition to the arsenal of biologics targeting TNF. Further clinical trials are needed to establish its safety and efficacy in patients, but the pre-clinical data is highly encouraging. With the increasing prevalence of TNF-driven diseases, Lenercept Biosimilar has the potential to make a significant impact on patient outcomes and improve their quality of life.

Lenercept Biosimilar - Anti-TNF fusion protein binds to TNFa / TNF-alpha, N-His, recombinant protein in indirect ELISA Assay

Immobilized TNFa / TNF-alpha, N-His, recombinant protein (cat. No.PX-P5961) at 0.5µg/mL (100µL/well) can bind to Lenercept Biosimilar - Anti-TNF fusion protein (cat. No.PX-TA2017) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450